At a glance
ClinicalIndex Comparison RecordPhase 2Unknown· 89 target
Drug / intervention
GLS-010drug
Likely dose
GLS-010 240mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open, Multi-center, Single-arm Phase II Clinical Study to Evaluate the Efficacy and Safety of Recombinant Fully Human Anti-PD-1 Monoclonal Antibody (GLS-010 Injection) in Patients With Recurrent or Metastatic Cervical Cancer
In Brief
A Phase 2 clinical trial evaluating GLS-010 for Cervical Cancer. Targeting 89 participants across 1 site.
Detailed Summary
Patients with recurrent or metastatic cervical cancer，and will be treated with GLS-010.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCervical Cancer
CountriesChina
Collaborators--
Timeline
Phase 2UnknownOverdue
2020202120222023202420252026
Enrollment StartMay 2019
First PostedJun 2019
Primary CompletionMay 2022
Study CompletionMay 2023
TodayJul 2026
First PostedJun 4, 2019
Enrollment StartMay 15, 2019
Primary CompletionMay 15, 2022
Study CompletionMay 15, 2023
TodayJul 1, 2026
Enrollment to primary: 3 yearsPosted 7.1 years ago
Interventions
GLS-010drug
Patients will be given 240mg GLS-010 every treatment.